144. Clinical Validation and Performance of a T-cell Immunosequencing Assay to Identify Past SARS-CoV-2 Infection
Sign Up to like & getrecommendations! Published in 2021 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofab466.144
Abstract: Abstract Background Our understanding of the SARS-CoV-2 immune response has critical gaps that are inadequately addressed with available tools. We report the clinical performance of T-Detect COVID, the first T-cell assay to identify prior SARS-CoV-2… read more here.
Keywords: biotechnologies employee; phd adaptive; employee shareholder; adaptive biotechnologies ... See more keywords
Gastrointestinal Tract Microbiome Dynamics Following Treatment with SER-109, an Investigational Oral Microbiome Therapeutic to Reduce the Recurrence of Clostridium difficile Infection (CDI)
Sign Up to like & getrecommendations! Published in 2017 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofx163.968
Abstract: Abstract Background Recurrence of CDI occurs within a few weeks after treatment due to antibiotic-induced dysbiosis. SER-109, an investigational, first-in-class microbiome drug, was designed to sustain a clinical response through microbiome restoration with a purified… read more here.
Keywords: employee shareholder; salary stock; seres therapeutics; shareholder salary ... See more keywords
LB19. Progress Toward a Vaccine for Maternal Immunization to Prevent Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Illness (LRTI) in Infants
Sign Up to like & getrecommendations! Published in 2018 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofy229.2193
Abstract: Abstract Background RSV is the leading cause of infant LRTI and hospitalization worldwide. The greatest burden of severe disease is in term infants 30 days before delivery compared with those vaccinated later; RSV antibody t1/2… read more here.
Keywords: employee shareholder; lrti; respiratory; rsv ... See more keywords